Unknown

Dataset Information

Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma.


ABSTRACT:

Background

Thalidomide maintenance therapy after stem cell transplantation resulted in increased progression-free survival and overall survival in a few trials, but its role in non-transplant eligible patients with multiple myeloma remains unclear. This study assessed the impact of thalidomide-interferon in comparison to interferon maintenance therapy in elderly patients with multiple myeloma.

Design and methods

Of 289 elderly patients with multiple myeloma who were randomized to thalidomide-dexamethasone or melphalan-prednisolone induction therapy, 137 finally completed 9 cycles of induction therapy with stable disease or better and thereby qualified for maintenance treatment. Of these, 128 have been randomized to either thalidomide-interferon or interferon alone. Primary s

SUBMITTER: Ludwig H 

PROVIDER: S-EPMC2930957 | biostudies-literature | 2010 Sep

REPOSITORIES: biostudies-literature